Key result
Aromatase inhibitors linked to ~260% greater risk of peripheral endothelial function deterioration.
Why the study?
Data on long-term cardiovascular effects of aromatase inhibitors in breast cancer patients are limited and conflicting.
Does aromatase inhibitor treatment worsen peripheral endothelial function in postmenopausal women with breast cancer?
Observational (n=97)
Does aromatase inhibitor treatment worsen peripheral endothelial function in postmenopausal women with breast cancer?
Odds Ratio: 3.6 (95% CI 1.1–12.07)
Absolute Event Rate: 29% vs 11%
p-value: p=0.03
Aromatase inhibitors are associated with peripheral endothelial function deterioration in postmenopausal women with breast cancer, particularly those with a higher baseline cardiovascular risk factor burden.
AI use may worsen endothelial function in postmenopausal breast cancer patients, especially those with ≥3 CV risks; leaves open clinical event risk and needs prospective validation.
No takes yet. Share an insight, caveat, or question.
Maor et al. (2018) conducted an observational in Breast cancer (n=97). Aromatase inhibitors vs. No aromatase inhibitors was evaluated on Endothelial function deterioration (RHI deterioration of at least 20% from baseline) (OR 3.6, 95% CI 1.10-12.07, p=0.03). Treatment with aromatase inhibitors was associated with a significantly higher risk of peripheral endothelial function deterioration compared to no AI treatment (OR 3.6; 95% CI 1.10-12.07; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: